1,495 results match your criteria Current Oncology Reports[Journal]


Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia.

Curr Oncol Rep 2019 Apr 17;21(6):51. Epub 2019 Apr 17.

Houston Methodist Cancer Center/Weill Cornell Medicine, Outpatient Tower, Floor 24, 6445 Main Street, Houston, TX, 77030, USA.

Purpose Of Review: Aromatase inhibitor-induced arthralgia (AIA) is a very common syndrome which significantly affects breast cancer survivors' quality of life, and it often leads to non-compliance with aromatase inhibitor (AI) therapy. However, the treatment of AIA remains a clinical challenge. Here, we will review the current data for acupuncture and vitamin D in the management of AIA. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0795-1
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0795-1DOI Listing
April 2019
1 Read

Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of Head and Neck Cancer: Rationale and Implications.

Curr Oncol Rep 2019 Apr 17;21(6):52. Epub 2019 Apr 17.

Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

Purpose Of Review: The objectives of this article are to review the major changes in the staging of head and neck cancers and the rationale for the modifications.

Recent Findings: Information gathered from various institutional reports lead to a better understanding of the clinical and biological behavior of head and neck tumors, resulting in distinct outcomes, which were used to update the staging system. This article reviews the changes in the staging of head and neck cancers published in the 8th edition of the AJCC/UICC TNM staging system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0799-xDOI Listing

The Current and Evolving Role of Radiation Therapy for Central Nervous System Metastases from Breast Cancer.

Curr Oncol Rep 2019 Apr 16;21(6):50. Epub 2019 Apr 16.

Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, 75 Francis Street, ASB1, L2, Boston, MA, 02115, USA.

Purpose Of Review: For patients with breast cancer who develop brain metastases, radiation therapy (RT) provides local control. Here, we review the current role for central nervous system RT, particularly focusing on the evolving role for stereotactic radiosurgery (SRS).

Recent Findings: SRS treats only known CNS disease as opposed to whole-brain radiation therapy (WBRT), which treats the entire brain parenchyma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0803-5DOI Listing

Systemic Therapy of Central Nervous System Metastases of Breast Cancer.

Curr Oncol Rep 2019 Apr 8;21(6):49. Epub 2019 Apr 8.

Department of Medical Oncology, Division of Breast Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA, 02215, USA.

Purpose Of The Review: Historically, systemic treatment options for patients with breast cancer brain metastases have been very limited. This review focuses on important considerations for systemic therapy as well as ongoing clinical trials evaluating novel agents.

Recent Findings: For patients with hormone receptor-positive brain metastases, endocrine therapy or chemotherapy options can be considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0802-6DOI Listing
April 2019
1 Read

Cardiovascular Disease and Cancer: Is There Increasing Overlap?

Curr Oncol Rep 2019 Apr 6;21(6):47. Epub 2019 Apr 6.

Division of Cardiology, Department of Medicine, University of Washington Medical Center, 1959 NE Pacific Street, Health Sciences Building, Suite No. AA-510A, Box 356422, Seattle, WA, 98195, USA.

Purpose Of Review: Cancer and cardiovascular disease are the leading causes of mortality in the USA. In this review, we highlight these shared disease pathways and provide a framework for a systems-based approach to reduce overall risk burden.

Recent Findings: From traditional risk factors such as age and tobacco use to more recently recognized entities including clonal hematopoiesis, we are gaining insights into shared mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0796-0DOI Listing
April 2019
1 Read

Qigong or Tai Chi in Cancer Care: an Updated Systematic Review and Meta-analysis.

Curr Oncol Rep 2019 Apr 6;21(6):48. Epub 2019 Apr 6.

Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong, China.

Purpose Of Review: Qigong and Tai Chi are two increasingly popular mind-body interventions with the potential to address the multifaceted needs of cancer survivors. The aim of this updated review and meta-analysis was to quantitatively evaluate the treatment effects of Qigong/Tai Chi on cancer survivors since 2014.

Recent Findings: There were statistically significant and clinically meaningful effects in favor of Qigong/Tai Chi interventions for symptoms of fatigue and sleep quality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0786-2DOI Listing

Cervical Esophageal Cancers: Challenges and Opportunities.

Curr Oncol Rep 2019 Apr 4;21(5):46. Epub 2019 Apr 4.

Department of Radiation Oncology, Mount Sinai Beth Israel, Suite 4G, 10 Union Square East, New York, NY, USA.

Purpose Of The Review: Cervical esophageal cancers (CECs) are a rare subset of esophageal cancers that are distinct in their management and outcomes. This review explores current data on the optimal management of this disease.

Recent Findings: While outcomes for CEC have been suboptimal, several strategies have been proven beneficial in recent years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0801-7DOI Listing

Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies.

Curr Oncol Rep 2019 Apr 4;21(5):45. Epub 2019 Apr 4.

Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, 12902 USF Magnolia Dr., MCB-CPT, Tampa, FL, 33612-9416, USA.

Purpose Of Review: The anticoagulation strategies for various cardiac-specific pathologies including atrial fibrillation are changing. Applying these strategies in patients with concomitant active cancer requires additional considerations. Here, we review the most recent changes in the anticoagulation management of common cardiac diseases and their application in cancer patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0797-z
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0797-zDOI Listing
April 2019
10 Reads

The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma.

Curr Oncol Rep 2019 Apr 2;21(5):44. Epub 2019 Apr 2.

Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave - CA6, Cleveland, OH, 44195, USA.

Purpose Of Review: Diffuse large B cell lymphoma (DLBCL) is characterized by clinical heterogeneity that is not fully accounted for by pathologic features. Furthermore, real-time treatment modifications and detection of relapse are typically guided by radiographic imaging modalities which are imperfect. Here, we review the potential utility of minimal residual disease (MRD) assessment for informing treatment decisions and detecting relapse. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0792-4
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0792-4DOI Listing
April 2019
6 Reads

Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.

Curr Oncol Rep 2019 Mar 27;21(5):42. Epub 2019 Mar 27.

Prostate Cancer Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), Cellex Center, Natzaret 115-117, 08035, Barcelona, Spain.

Purpose Of Review: Genomic studies of localized and metastatic prostate cancer have identified a high prevalence of clinically actionable alterations including mutations in DNA repair genes. In this manuscript, we review the current knowledge on DNA repair defects in prostate cancer and provide an overview of how these alterations can be targeted towards a personalized prostate cancer management.

Recent Findings: Twenty to 25% of metastatic prostate cancers harbor defects in DNA repair genes, most commonly in the homologous recombination genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0790-6DOI Listing

Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.

Curr Oncol Rep 2019 Mar 27;21(5):43. Epub 2019 Mar 27.

Sir Peter MacCallum Department of Oncology, University of Melbourne, 305 Grattan Street, Peter MacCallum Cancer Center, Melbourne, Victoria, 3000, Australia.

Purpose Of Review: Systemic therapy for patients with hormone-sensitive oligometastatic prostate cancer is non-curative and associated with toxicities. Meanwhile, this population presents unique clinical opportunities to improve outcomes, including the demonstrated benefits of radiotherapy to the primary tumor or oligometastatic sites.

Recent Findings: Recently published randomized studies have demonstrated benefits with the addition of radiotherapy to the primary disease or metastatic lesions in patients with synchronous or metachronous disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0791-5DOI Listing
March 2019
1 Read

Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma.

Curr Oncol Rep 2019 Mar 27;21(5):39. Epub 2019 Mar 27.

Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.

Purpose Of Review: Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients.

Recent Findings: Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0788-0DOI Listing
March 2019
1 Read

Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.

Curr Oncol Rep 2019 Mar 27;21(5):38. Epub 2019 Mar 27.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX, 77030, USA.

Purpose Of Review: Chimeric antigen receptor (CAR) T cells are a form of adoptive therapy employing autologous T cells engineered with an artificial receptor, able to recognize tumor antigens through an HLA-independent mechanism. We will review data on safety and efficacy outcomes with CAR T cell therapy in lymphomas.

Recent Findings: Multicenter trials evaluating three CAR T cell products targeting CD19 have shown that they are highly effective and induce durable remissions in a substantial proportion of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma (NHL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0789-zDOI Listing
March 2019
1 Read

The Impact of Obesity on Breast Cancer Diagnosis and Treatment.

Curr Oncol Rep 2019 Mar 27;21(5):41. Epub 2019 Mar 27.

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer, 1500 E Duarte Rd, Duarte, CA, 91010, USA.

Purpose Of Review: Obesity is a recognized risk factor for the development of breast cancer and recurrence even when patients are treated appropriately. We reviewed the literature that addresses the impact of obesity on diagnosis and the individual therapeutic interventions, and present a summary of the findings.

Recent Findings: Compared to non-obese women with breast cancer, obese women with breast cancer have a worse disease-free and overall survival despite appropriate local and systemic therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0787-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437123PMC

Central Nervous System Involvement of Natural Killer and T Cell Neoplasms.

Curr Oncol Rep 2019 Mar 27;21(5):40. Epub 2019 Mar 27.

Department of Neurology, Indiana University Health, Indiana University School of Medicine, 355 W. 16th St., Ste 3200, Indianapolis, IN, 46202, USA.

Purpose Of Review: Peripheral natural killer (NK) and T cell neoplasms comprise approximately 10-15% of non-Hodgkin lymphomas. There are 27 different subtypes of peripheral NK and T cell neoplasms, each of which is relatively uncommon. Treatment has been largely extrapolated from case series, retrospective reports, and paradigms developed for the aggressive B cell lymphomas. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0794-2
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0794-2DOI Listing
March 2019
2 Reads

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.

Curr Oncol Rep 2019 Mar 23;21(4):37. Epub 2019 Mar 23.

Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Purpose Of Review: Immune checkpoint therapy has dramatically changed the therapeutic landscape of solid malignancies. Here, we review the scientific rationale and current data evaluating immune checkpoint inhibitors in acute myeloid leukemia (AML).

Recent Findings: Immune checkpoint inhibitor monotherapy has shown limited clinical activity in AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0781-7DOI Listing
March 2019
1 Read

Targeting Barriers of Systems of Care in a Growing Multi-disciplinary Field.

Curr Oncol Rep 2019 Mar 11;21(4):36. Epub 2019 Mar 11.

Cardio-Oncology Program, MedStar Heart and Vascular Institute, Georgetown University, 110 Irving Street, NW, Ste. 1218, Washington, DC, 20010, USA.

Purpose Of Review: Cardio-oncology is a growing multi-disciplinary field that focuses on treating and preventing cardiovascular complications in cancer survivors and patients. This review summarizes the current clinical needs and system-based approaches to target barriers of care.

Recent Findings: The field of cardio-oncology has experienced significant growth in recent years, and an increasing number of programs have been developed across the nation to provide improved and multi-disciplinary care to this patient population. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0785-3
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0785-3DOI Listing
March 2019
6 Reads

Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.

Curr Oncol Rep 2019 Mar 8;21(4):35. Epub 2019 Mar 8.

Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, 400 Parnassus Ave, Box 0324, San Francisco, CA, 94143, USA.

Purpose Of Review: Hematologic malignancies are common and difficult to treat in older adults. In this review, we focus on recent updates in diseases with several novel agents relevant to older adults-acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM).

Recent Findings: In AML, CPX-351 offers a new induction chemotherapy for secondary AML that prolongs survival, and venetoclax and IDH inhibitors are efficacious and well tolerated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0778-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438699PMC
March 2019
3 Reads

Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.

Curr Oncol Rep 2019 Mar 8;21(4):34. Epub 2019 Mar 8.

Yale Comprehensive Cancer Center, 333 Cedar Street, New Haven, CT, 06520, USA.

Purpose Of Review: Renal cell carcinoma (RCC) was recognized as an immunologically sensitive cancer over 30 years ago. The first therapies to affect the course of RCC were cytokines (interferon alfa-2B and interleukin-2). Subsequently, drugs that inhibit HIF (hypoxia-inducible factor)/VEGF (vascular endothelial growth factor) signaling demonstrated overall survival advantages (tyrosine kinase inhibitors and mTor inhibitors). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0779-1
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0779-1DOI Listing
March 2019
2 Reads

Evidence-Based Practice: Temozolomide Beyond Glioblastoma.

Curr Oncol Rep 2019 Mar 5;21(4):30. Epub 2019 Mar 5.

Department of Neurology, University of Michigan, 1500 E. Medical Center Dr., 1914 Taubman Center, Ann Arbor, MI, 48109, USA.

Purpose Of Review: Temozolomide is a first-line treatment for newly diagnosed glioblastoma. In this review, we will examine the use of temozolomide in other contexts for treating gliomas, including recurrent glioblastoma, glioblastoma in the elderly, diffuse low- and high-grade gliomas, non-diffuse gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma.

Recent Findings: Temozolomide improved survival in older patients with glioblastoma, anaplastic gliomas regardless of 1p/19q deletion status, and progressive ependymomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0783-5DOI Listing
March 2019
2 Reads

Novel Imaging in Detection of Metastatic Prostate Cancer.

Curr Oncol Rep 2019 Mar 5;21(4):31. Epub 2019 Mar 5.

Molecular Imaging Program, National Cancer Institute, NIH, Building 10 - Room B3B85, Bethesda, MD, 20892, USA.

Purpose Of Review: This review aims to highlight the limitations of current standard-of-care prostate cancer (PCa) imaging and discuss novel clinical imaging in advanced disease.

Recent Findings: PCa staging through imaging is important for proper selections in clinical treatment. Traditional imaging techniques for metastatic disease (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0780-8DOI Listing
March 2019
6 Reads

Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.

Curr Oncol Rep 2019 Mar 5;21(4):29. Epub 2019 Mar 5.

Department of Internal Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.

Purpose Of Review: Multiple myeloma is a common hematologic malignancy characterized by recurrent relapsing disease course requiring use of various therapies. Over the past few decades, significant advancements in the treatment of myeloma have occurred including routine use of proteasome inhibitors and immunomodulatory drugs. These have effectively improved survival; however, some also have increased risk of cardiovascular toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0784-4DOI Listing
March 2019
9 Reads

Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions.

Authors:
Lawrence J Solin

Curr Oncol Rep 2019 Mar 5;21(4):33. Epub 2019 Mar 5.

Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Purpose Of Review: Ductal carcinoma in situ (DCIS; intraductal carcinoma) of the breast is commonly found in an asymptomatic woman on routine screening mammography. The purpose of this review is to describe current approaches to the management of DCIS as well as areas for future investigation.

Recent Findings: Randomized trials have demonstrated that adding radiation treatment after breast conservation surgery (lumpectomy; surgical excision) reduces the rate of ipsilateral local recurrence by about half, and that adding hormonal therapy reduces the rate of all breast cancer events (ipsilateral plus contralateral). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0777-3DOI Listing
March 2019
7 Reads

Cancer Biomarkers for Integrative Oncology.

Curr Oncol Rep 2019 Mar 5;21(4):32. Epub 2019 Mar 5.

Department of Medicine, Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15232, USA.

Purpose Of Review: There has been an increasing interest in using complementary and alternative medicine (CAM) approaches to treat cancer. It is therefore relevant and timely to determine if CAM biomarkers can be identified and developed to guide cancer diagnosis and treatment. Herein, we review the status of cancer biomarkers in CAM research and treatment to stimulate further research in this area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0782-6DOI Listing
March 2019
1 Read

Cardiac Complications in the Adult Bone Marrow Transplant Patient.

Curr Oncol Rep 2019 Mar 2;21(3):28. Epub 2019 Mar 2.

UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.

Purpose Of Review: Due to advancements in oncologic treatment strategies and techniques, the number of survivors who have undergone hematopoetic stem cell transplant (HCT) continues to increase in the United States; this number is projected to reach 502,000 by the year 2030. There is significant interest within the field of cardio-oncology to identify cardiotoxicity and cardiovascular disease in the HCT population. Epidemiologic studies analyzing both short- and long-term cardiovascular effects, risk stratification modeling, cardioprotective strategies, and expert consensus documents for cardiotoxicity surveillance recommendations are reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0774-6DOI Listing
March 2019
2 Reads

Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development.

Curr Oncol Rep 2019 Feb 26;21(3):22. Epub 2019 Feb 26.

The University of Oklahoma Stephenson Cancer Center, 800 NE 10th Street, Oklahoma City, OK, 73104, USA.

Purpose Of Review: The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition.

Recent Findings: Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0771-9DOI Listing
February 2019
2 Reads

Sinonasal Undifferentiated Carcinoma.

Curr Oncol Rep 2019 Feb 26;21(3):26. Epub 2019 Feb 26.

Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1445, Houston, TX, 77030, USA.

Purpose Of Review: To provide a comprehensive review of the literature highlighting the recent advances in the diagnosis and management of sinonasal undifferentiated carcinoma (SNUC) RECENT FINDINGS: SNUC usually presents at advanced stage and the prognosis is usually poor with high rates of locoregional recurrence and tendency to metastasize. Special attention should be made in differentiating SNUC from other sinonasal malignancies in order to guide the appropriate treatment accordingly. Multimodality treatment is usually recommended for treating SNUC. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0776-4
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0776-4DOI Listing
February 2019
5 Reads

Clinical and Genomic Considerations for Variant Histology in Bladder Cancer.

Curr Oncol Rep 2019 Feb 26;21(3):23. Epub 2019 Feb 26.

Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1373, Houston, TX, 77030, USA.

Purpose Of Review: Urothelial carcinoma demonstrates remarkable plasticity in its ability to differentiate into divergent histologic subtypes in both a pure and mixed form. This review presents the most current data pertaining to bladder cancer with variant histology.

Recent Findings: Recognition of bladder cancer variants has increased profoundly in the past two decades with their inclusion in the pathologic guidelines and increased awareness among pathologists and urologists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0772-8DOI Listing
February 2019
1 Read

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.

Curr Oncol Rep 2019 Feb 26;21(3):25. Epub 2019 Feb 26.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Lawrence House 304, 10 North Grove St, Boston, MA, 02114, USA.

Purpose Of Review: To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current controversies and evolving areas of research.

Recent Findings: Palbociclib, ribociclib, and abemaciclib are each approved in combination with an aromatase inhibitor or fulvestrant for HR+ MBC. Abemaciclib is also approved as monotherapy for pre-treated patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0769-3DOI Listing
February 2019

Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma.

Curr Oncol Rep 2019 Feb 26;21(3):24. Epub 2019 Feb 26.

Department of Medicine, NYU School of Medicine, New York, NY, USA.

Purpose Of Review: Since 2016, five new programmed cell death protein 1/ligand 1 (PD-1/L1) checkpoint inhibitors have been approved for metastatic urothelial carcinoma. This review will summarize the data supporting the widespread use of these agents and highlight areas of ongoing clinical development.

Recent Findings: PD-1/L1 axis inhibition has demonstrated clear superiority to chemotherapy for the treatment of metastatic urothelial cancer in the second-line setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0775-5DOI Listing
February 2019

How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy Strategy.

Curr Oncol Rep 2019 Feb 26;21(3):27. Epub 2019 Feb 26.

Department of Hematology, Pitié-Salpétrière Hospital APHP, Sorbonne Université, Boulevard de l'hôpital, 75013, Paris, France.

Purpose Of Review: Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder. Up to now, therapeutic choice was not influenced by the biological characteristics of the disease. Here, we will review how recent advances in biology in WM may affect therapy strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0768-4DOI Listing
February 2019

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.

Curr Oncol Rep 2019 Feb 26;21(3):21. Epub 2019 Feb 26.

Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.

Purpose Of Review: Lung cancer remains the leading cause of cancer-related mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) has led to the discovery of actionable oncogenic driver alterations, which has revolutionized treatment for this disease. This review will move beyond traditional mutational drivers such as EGFR and ALK and will instead focus on emerging targets and the efficacy of new precision therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0770-xDOI Listing
February 2019
2 Reads

Management of Adrenocortical Carcinoma.

Curr Oncol Rep 2019 Feb 23;21(3):20. Epub 2019 Feb 23.

Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1461, Houston, TX, 77030, USA.

Purpose Of Review: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy typically with poor prognosis. This review aims to summarize the current knowledge regarding the clinical management of ACC.

Recent Findings: Surgery remains the cornerstone for localized ACC management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0773-7DOI Listing
February 2019
1 Read

Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics.

Curr Oncol Rep 2019 Feb 21;21(2):19. Epub 2019 Feb 21.

ARMO Biosciences, Redwood City, CA, USA.

Purpose Of Review: Interleukin-10 (IL-10) is a cytokine with anti-inflammatory properties, which induces activation and proliferation of antigen-activated intratumoral CD8+ T cells. This review discusses the evolution of pegylated IL-10 (pegilodecakin) from preclinical investigation through first-in-human studies in oncology.

Recent Findings: Pegilodecakin was evaluated across multiple advanced solid tumors in a large phase 1/1b trial alone and in combination with chemotherapy or anti-PD-1 antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0760-zDOI Listing
February 2019
1 Read

Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid.

Curr Oncol Rep 2019 Feb 4;21(2):18. Epub 2019 Feb 4.

Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave./CA60, Cleveland, OH, 44195, USA.

Purpose Of Review: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients, and its management is often associated with complications including risk of recurrent VTE and bleeding. Here, we review the current data on pitfalls during anticoagulation in cancer patients and measures necessary to avoid them.

Recent Findings: Although low-molecular-weight heparin monotherapy has been the standard of treatment for several years, emerging data for direct oral anticoagulants (DOACs) are leading to new paradigms in treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0767-5DOI Listing
February 2019
1 Read

New Treatment Options for Acute Myeloid Leukemia in 2019.

Curr Oncol Rep 2019 Feb 4;21(2):16. Epub 2019 Feb 4.

Department of Hematology, Hopital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris Diderot University, Paris, France.

Purpose Of Review: The extensive genomic characterization of acute myeloid leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We review relevant data that have led to recent approval of new targeted therapies in AML and discuss the most promising drugs currently in development in this disease.

Recent Findings: New formulations of cytotoxic agents, namely CPX-351 and gemtuzumab ozogamicin, improve the outcome of defined subgroup of patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0764-8
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0764-8DOI Listing
February 2019
31 Reads

Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.

Curr Oncol Rep 2019 Feb 4;21(2):12. Epub 2019 Feb 4.

Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, 91766, USA.

Purpose Of Review: Review current understanding of both canonical and non-canonical Wnt signaling in cancer and provide updated knowledge in current clinical trials of Wnt signaling drugs.

Recent Findings: Important roles of both canonical and non-canonical Wnt signaling in cancer have been increasingly recognized. Recent clinical trials of several Wnt-signaling drugs have showed promising outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0763-9DOI Listing
February 2019

BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.

Curr Oncol Rep 2019 Feb 4;21(2):13. Epub 2019 Feb 4.

Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500, Bellinzona, Switzerland.

Purpose Of Review: Increasing evidence suggests that epigenome plays a central role in cancer development making it a promising target for anticancer treatments. Here, we review two new classes of epigenome-targeting agents: the bromodomain and extraterminal domain proteins (BET) inhibitors and the enhancer of zeste homolog (EZH2) inhibitors.

Recent Findings: Clinical research evaluating BET and EZH2 inhibitors is still at an early stage; however, both classes of drugs have demonstrated activity among different hematologic malignancies and solid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0762-xDOI Listing
February 2019

Communicating with Adolescents and Young Adults about Cancer-Associated Weight Loss.

Curr Oncol Rep 2019 Feb 4;21(2):15. Epub 2019 Feb 4.

School of Medicine, Geelong Waurn Ponds Campus, Locked Bag 20000, Geelong, VIC, 3220, Australia.

Purpose Of Review: Over the past two decades, advances have been made in understanding the pathophysiology of cancer-associated weight loss, termed "cachexia." To date, there is no proven effective intervention to completely reverse cachexia and there are no approved drug therapies to treat it. This paper will review relevant literature in relation to communicating with adolescents and young adults about cancer-associated weight loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0765-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400873PMC
February 2019
4 Reads

Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?

Curr Oncol Rep 2019 Feb 4;21(2):17. Epub 2019 Feb 4.

Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Belisario Dominguez Sección XVI, Tlalpan, 14080, Mexico City, Mexico.

Purpose Of Review: The purpose of this review is to discuss the current recommendations for the use of bispecific antibodies (bsAb) in hematologic malignancies and explore the future in this field.

Recent Findings: Bispecific antibodies are molecules able to target two different antigen-binding sites: one towards a tumor antigen and another to activate a cytotoxic cell. Phase II/III trials on blinatumomab for acute lymphoblastic leukemia (ALL) have demonstrated its efficacy for treating minimal residual disease (MRD+) and relapsed refractory (r/r) Philadelphia positive (Ph+) and negative (Ph-) ALL in adults and children. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0759-5
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0759-5DOI Listing
February 2019
13 Reads

TRK Inhibitors: Clinical Development of Larotrectinib.

Curr Oncol Rep 2019 Feb 4;21(2):14. Epub 2019 Feb 4.

Scripps Clinic, Division of Hematology-Oncology, 10666 North Torrey Pines Road, La Jolla, CA, 92037, USA.

Purpose Of Review: In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK fusion-positive tumors.

Recent Findings: The tropomyosin receptor kinase family, TrkA, TrkB, and TrkC, transmit extracellular signals via a variety of intracellular pathways to promote normal neuronal development. TrkA, B, and C are encoded by NTRK1, 2, and 3, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0761-yDOI Listing
February 2019
5 Reads

Novel Approaches for Treating Pain in Children.

Authors:
William Splinter

Curr Oncol Rep 2019 Feb 4;21(2):11. Epub 2019 Feb 4.

Palliative Medicine, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada.

Purpose Of Review: Good pain management in children, especially those at end of life, is a crucial component of palliative medicine. The current review assesses some of the new and/or innovative ways to manage pain in children. The article focuses on some recent medications/pharmaceutical options such as cannabinoids and also innovative ways to administer medication to children, such as intranasal and inhalation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0766-6DOI Listing
February 2019
4 Reads

A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety.

Curr Oncol Rep 2019 Feb 1;21(1):10. Epub 2019 Feb 1.

Park Nicollet Oncology Research, HealthPartners Institute, Frauenshuh Cancer Center, 3800 Park Nicollet Blvd, Minneapolis, MN, 55416, USA.

Purpose Of Review: As the legalization of medical cannabis continues across the USA, oncology care providers will be increasingly asked to provide recommendations regarding its use in the cancer setting. In this article, we review recent literature that analyzes cannabis use specifically in patients with cancer and provide an accessible guide for clinicians, researchers, and patients.

Recent Findings: We aimed to answer questions about the availability of cannabis in the USA, the trials supporting its use in the cancer setting, and the important factors to consider related to safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0757-7DOI Listing
February 2019

Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.

Curr Oncol Rep 2019 Jan 30;21(1). Epub 2019 Jan 30.

Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.

Purpose Of Review: Cardiovascular effects from cancer treatment remains a leading cause of treatment-associated morbidity and mortality among cancer survivors. The National Cancer Institute and National Heart, Lung, and Blood Institute convened a Workshop in June 2018 entitled "Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity" to highlight progress, ongoing work, and update scientific priorities since the 2013 Workshop. Here we will describe these advances and provide an overview of the research priorities identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0751-0DOI Listing
January 2019

Plasma Cell Leukemia: Definition, Presentation, and Treatment.

Curr Oncol Rep 2019 Jan 28;21(1). Epub 2019 Jan 28.

Department of Hematology, Odense University Hospital, Kloevervaenget 10, 12th floor, DK-5000, Odense C, Denmark.

Purpose Of Review: We discuss current topics on the definition of plasma cell leukemia and the distinction between plasma cell leukemia and multiple myeloma. Moreover, we review the latest literature on how to treat plasma cell leukemia.

Recent Findings: Plasma cell leukemia is clinically and genetically distinct from multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0754-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349791PMC
January 2019

On Heartbreak in Oncology.

Authors:
Daniel Rayson

Curr Oncol Rep 2019 Jan 25;21(1). Epub 2019 Jan 25.

Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Room 457A Bethune Building, 1276 South Park St., B3H2Y9, Halifax, Nova Scotia, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0755-9
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0755-9DOI Listing
January 2019
11 Reads

HIF Inhibitors: Status of Current Clinical Development.

Curr Oncol Rep 2019 Jan 22;21(1). Epub 2019 Jan 22.

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk CA60, Cleveland, OH, 44195, USA.

Purpose Of Review: In this review, the importance of the hypoxia inducible factor (HIF) pathway in tumorigenesis and cancer treatment outcomes will be discussed. The outcomes of phase II and III clinical trials of direct HIF inhibitors in the treatment of cancer will be reviewed.

Recent Findings: The HIF signaling pathway is activated by tumor-induced hypoxia or by inactivating mutations of the VHL gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0752-zDOI Listing
January 2019
104 Reads
2.891 Impact Factor

Management of Residual Mass in Germ Cell Tumors After Chemotherapy.

Curr Oncol Rep 2019 Jan 21;21(1). Epub 2019 Jan 21.

Department of Urology, Indiana University School of Medicine, 535 Barnhill Dr., Indianapolis, IN, 46202, USA.

Purpose Of Review: The purpose of this review is to educate medical oncologists on the management of patients with residual germ cell tumors and the role of surgical resection after platinum-based chemotherapy.

Recent Findings: Patients with non-seminomatous testicular cancer and residual enlarged retroperitoneal lymph nodes > 1 cm following induction chemotherapy with normal tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. All patients with primary mediastinal non-seminoma should undergo surgical resection of the mediastinal mass post-chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0758-6DOI Listing
January 2019
3 Reads

Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.

Curr Oncol Rep 2019 Jan 21;21(1). Epub 2019 Jan 21.

Gehr Family Center for Leukemia Research, City of Hope, 1500 Duarte Rd, Duarte, CA, 91010, USA.

Purpose Of Review: T cell-based therapies (blinatumomab and CAR T cell therapy) have produced unprecedented responses in relapsed and refractory (r/r) acute lymphoblastic leukemia (ALL) but is accompanied with significant toxicities, of which one of the most common and serious is cytokine release syndrome (CRS). Here we will review the pathophysiology, prevention, and treatment of CRS.

Recent Findings: Efforts have been initiated to define and grade cytokine release syndrome (CRS), to identify patients at risk, to describe biomarkers that predict onset and severity, to understand the pathophysiology, and to prevent and treat severe cases to reduce T cell immunotherapy-related morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0753-yDOI Listing
January 2019

Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.

Curr Oncol Rep 2019 Jan 18;21(1). Epub 2019 Jan 18.

Genetic Pathology Evaluation Centre, Department of Pathology & Laboratory Medicine, University of British Columbia, 509-3660 Oak St, Vancouver, BC, V5Z 1M9, Canada.

Purpose Of Review: This review focuses on the recent clinical development of indolamine-2,3-dioxygenase-1 (IDO-1) inhibitors.

Recent Findings: IDO-1 alters tryptophan metabolism in a manner enhancing T-regulatory cell activity, but pre-clinical data show that its role in tumorigenesis is context-dependent on host and tumor interaction, highlighting some challenges in understanding the molecular oncology of this enzymatic drug target. Because results from phase I/II trials of IDO-1 inhibitor monotherapy have been disappointing, current clinical trials employ IDO-1 inhibitors in combination strategies with other immunotherapy agents or with chemotherapy ± radiation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0750-1
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0750-1DOI Listing
January 2019
8 Reads